on prevention, detection, evaluation, and treatment of high BP published an updated guideline for the management of high BP in adults. 5 One of the major changes was a revision of the systolic BP target from 140 to 150 mm Hg in patients aged ≥60 years and without diabetes mellitus (DM) or chronic kidney disease (CKD). On the basis of a systematic review of available randomized controlled trials, the panel used rigorous evidence-based methods and developed evidence statements and recommendations for BP treatment, but did not consider data from the population-based cohort studies. Members of the JNC8 panel who disagreed with this new recommendation published their minority opinion on this controversial revision in the systolic BP (SBP) threshold. 6 Recently, the Systolic Blood Pressure Intervention Trial (SPRINT) was terminated early and demonstrated that lowering of SBP to 120 mm Hg reduced rates of major cardiovascular events and all-cause mortality in older or high-risk patients who did not have DM; however, no significant reduction was observed for stroke events alone. Abstract-In 2014, the Eighth Joint National Committee revised the target maximum systolic blood pressure (SBP) from 140 to 150 mm Hg in patients aged ≥60 years without diabetes mellitus or chronic kidney disease. The evidence from cohort studies supporting this change was sparse, particularly among US minority populations. In the Northern Manhattan Study, 1750 participants aged ≥60 years and free of stroke, diabetes mellitus, and chronic kidney disease had SBP measured at baseline and were annually followed up for incident stroke. Mean age at baseline was 72±8 years, 63% were women, 48% Hispanic, 25% non-Hispanic white, and 25% non-Hispanic black. Among all participants, 40% were on antihypertensive medications; 43% had SBP <140 mm Hg, 20% had 140 to 149 mm Hg, and 37% had ≥150 mm Hg. Over a median follow-up of 13 years, 182 participants developed stroke. 
H ypertension is a well-established major risk factor for stroke, one of the leading causes of death and disability in the United States and worldwide. 1 Hypertension is also an important contributor to substantial disparities in the mortality and incidence of stroke across race and ethnic subgroups, with greater burdens among blacks and Hispanics. 2, 3 Given that elevated blood pressure (BP) is a modifiable risk factor amenable to lifestyle interventions and relatively inexpensive medications, evidence-based BP management is an important strategy for the prevention of stroke and the reduction of race-ethnic stroke disparities. Although there is a clinical emphasis on the detection of hypertension, most epidemiological studies have shown that BP is a continuous vascular risk factor and even modest elevations are associated with increased stroke risk.
Given that the evidence leading to the recommendations for hypertension treatment has largely been derived from white cohorts, 1 concern is the potential differential impact of the increasing systolic BP treatment threshold across raceethnic groups. 8 The Northern Manhattan Study (NOMAS) is a prospective population-based cohort study that represents a multiethnic community with a significant proportion of Hispanics, the fastest growing and largest minority group in the United States. Using NOMAS data, we sought to assess this SBP modification by evaluating incident stroke risk for systolic BP levels of 140 to 149 mm Hg among those aged ≥60 years without stroke, DM, or CKD.
Methods

Study Population
The present study included a subsample of 1750 participants who were aged ≥60 years and free of stroke, DM, and CKD at baseline from the NOMAS. Details of the NOMAS study design have been published previously. [9] [10] [11] The original cohort included 3298 strokefree participants enrolled from 1993 to 2001. Written informed consent was obtained from all the participants, and the study was approved by the Institutional Review Boards of the University of Miami and Columbia University Medical Center.
Baseline Characteristics
At baseline, all participants underwent a thorough evaluation that included medical history, physical examination, review of medical records, and tests of fasting blood samples. Self-reported race-ethnicity was classified based on a series of questions modeled after the US census. Standardized questions on hypertension, DM, and cardiac conditions were adapted from the Centers for Disease Control and Prevention Behavioral Risk Factor Surveillance System. 12 Office SBP and diastolic BP (DBP; mean of 2 readings in sitting position) were measured by trained research assistants after a period of rest with a mercury sphygmomanometer. Fasting blood glucose was measured with standard procedures using a glucose dehydrogenase method. 13 DM was defined by taking antiglycemic medications or fasting blood glucose >125 mg/dL. Serum creatinine was measured using the kinetic alkaline picrate assay (Jaffé reaction). Baseline kidney function was assessed using estimated glomerular filtration rate based on the Modification of Diet in Renal Disease formula: estimated glomerular filtration rate=186.3×(serum creatinine 14 CKD was defined as estimated glomerular filtration rate <60 mL/min per 1.73 m 2 . Smoking status was categorized into never, former, and current (within a year) based on self-reported age of starting smoking and age of quitting smoking. Moderate alcohol consumption was defined as 1 drink/mo ≤2 drinks/ day. Leisure-time physical activity was evaluated using a questionnaire adapted from the National Health Interview Survey.
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Ascertainment of Incident Stroke Events
The primary outcome was any incident stroke. Follow-up procedures and stroke classifications have been published previously. 16 In brief, NOMAS participants have been followed up annually by telephone interviews with an average annual contact rate of 99%. 17 The outcome surveillance network also includes daily screening of admissions, review of neurology consult lists, hospital admission, and discharge data (including screening of International Classification of DiseasesNinth codes), emergency room visits, and visits to the ambulatory care network. Patients who screen positive for any potential cardiac or neurological event undergo in-person assessment, chart review, and examination by a study neurologist. Incident stroke events were verified and classified as the first occurrence of stroke by at least 2 NOMAS vascular neurologists as described in the previous report.
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Data Analysis
The present study included participants who were aged ≥60 years of age, without stroke, DM, or CKD at baseline. The participants were divided into 3 groups based on their baseline SBP level (<140, 140-149, and ≥150 mm Hg). The primary outcome was first-ever stroke during follow-up. All covariates were measured at baseline.
For the baseline characteristics, we used the F test to examine the differences in continuous variables and the χ 2 test to compare the frequencies of categorical variables among the SBP groups. For each participant, we calculated the person-time at risk accrued from baseline to the time of incident stroke, death, loss to follow-up, or the most recent follow-up date up to July 2014, whichever came first. For association between SBP levels and incident stroke risk, we used Kaplan-Meier curves to describe the unadjusted association and Cox proportional hazards models to estimate the multivariable-adjusted hazard ratios with 3 sequential models. Model 1 was adjusted for age, sex, and race-ethnicity; model 2 was additionally adjusted for antihypertensive medication use, waist circumference, smoking status, moderate alcohol drinking, leisure-time physical activity, and history of myocardial infarction, atrial fibrillation, and coronary heart disease; and model 3 was adjusted further for diastolic BP. As secondary analyses, we examined the association by excluding the individuals who were on baseline antihypertensive medication, excluding those who had elevated DBP >90, and by grouping the subjects into 3 categories based on both baseline SBP and DBP levels (SBP<140 and DBP<90 mm Hg; SBP 140-149 and DBP<90 mm Hg; and SBP≥150 or DBP≥90 mm Hg). Finally, given the difference in stroke risk across race-ethnic, sex, and age groups, 1, 18, 19 we conducted stratified analyses to explore the potential modifications by race-ethnicity, sex, and age. We performed all data analyses with SAS statistical software version 9.3 (SAS Institute Inc, Cary, NC).
Results
The baseline characteristics of 1750 NOMAS participants aged ≥60 years without stroke, DM, or CKD are presented in Table 1 by SBP levels and overall. The mean age of the participants was 72±8 years, 63% were women, 48% Hispanic, 25% non-Hispanic white, and 25% non-Hispanic black. Overall, 40% were on antihypertensive medications; 43% had SBP <140 mm Hg, 20% had 140 to 149 mm Hg, and 37% had ≥150 mm Hg. Univariate analysis showed that baseline SBP levels were associated with age, race-ethnicity, smoking status, waist circumference, antihypertensive medication use, and DBP level, but not with leisure-time physical activity, moderate alcohol drinking, or any history of cardiovascular diseases.
A total of 182 incident strokes (159 ischemic, 18 hemorrhagic, 3 subarachnoid, and 2 unknown) occurred during a median follow-up of 13 years (interquartile range, 7-15 years). The overall crude incidence rate was 9.1/1000 personyears ( Table 2 ). The crude stroke incidence was greater (P for log-rank test=0.002) among patients with SBP≥150 mm Hg (10.8/1000 person-years) and SBP 140 to 149 (12.3) than among those with SBP<140 (6.2). The Kaplan-Meier curves for the individuals with SBP≥150 mm Hg and 140 to 149 were closer to each other than they were to the curve for those with SBP <140 mm Hg ( Figure 1 ).
After adjusting for demographics, vascular risk factors, DBP, and antihypertensive medication use (model 3; Table 2 ), participants with SBP 140 to 149 mm Hg had increased risk of stroke (hazard ratio, 1.72; 95% CI, 1.15-2.57; P=0.008) when compared with those with SBP <140 mm Hg. No significant interactions were detected by race-ethnicity, sex, and age. For SBP 140 to 149 compared with <140 mm Hg, however, stratified analysis using model 3 showed an increased stroke risk in In another sensitivity analysis, we excluded 706 subjects with baseline antihypertensive medication use ( Figure 2C ). In this group, when compared with those with SBP <140, participants with SBP 140 to 149 mm Hg had increased risk of stroke with an hazard ratio ranging from 1.6 to 2.3 across race-ethnic, sex, and age groups. In addition, we regrouped the subjects into 3 categories based on their baseline SBP and DBP levels. The relative risk for SBP 140 to 149 mm Hg compared with SBP <140 mm Hg remained similar to the relative risk found by grouping the subjects based on baseline SBP levels and adjusting for DBP levels in both overall and stratified analyses (Table S1 in the online-only Data Supplement).
Discussion
In the present study conducted in a sample from the NOMAS multiethnic cohort with a median follow-up of 13 years, we demonstrated that the recent JNC8 recommendation for revising the SBP threshold from 140 to 150 mm Hg for hypertension treatment could have a detrimental effect on stroke risk and may contribute to stroke disparities across race-ethnicity and sex. The increased stroke risk for SBP between 140 and 149 mm Hg compared with SBP <140 mm Hg tended to be more prominent among Hispanics and non-Hispanic blacks than in non-Hispanic whites and was mainly observed among women, and also appeared among those aged >80 years where cautions have been raised about aggressive management of hypertension. When excluding all patients on any antihypertensive medications at baseline, there was a clear and consistent increased risk of stroke for those with SBP of 140 to 149 mm Hg when compared with those with SBP <140 across age, sex, and race-ethnic subgroups.
The JNC8 5 recommendation for raising the threshold 10 mm Hg above that in the previous guideline for SBP treatment in the general population who are ≥60 years and do not have DM or CKD raised a major concern. Although a recent study suggested that this recommendation would be cost-effective and may reduce side effects of medications and adverse events, 20 the JNC8 members who did not agree with this recommendation 6 argued that the increased SBP target of 150 mm Hg could reduce the intensity of antihypertensive treatment in a large population at high risk for cardiovascular disease and stroke, especially among high-risk populations such as blacks. 21 In the US population, BP is adequately controlled only in 36% of men and 28% of women between ages 60 and 79 years and in 38% of men and 23% of women aged ≥80 years. 21 A cross-sectional study 22 conducted in 16 372 subjects from the National Health and Nutrition Examination Survey demonstrated that the proportion of older adults (≥60 years) receiving BP-lowering medication and meeting the more stringent Following these results, other investigators raised the concern that JNC8 will lead to a higher incidence of cardiovascular events and mortality, especially in more vulnerable populations. 23 Previous published data from INVEST (International Verapamil SR-Trandolapril Study) 24 showed that among hypertensive patients with coronary artery disease who are ≥60 year, achieving a BP of <150 mm Hg as recommended by JCN8, was associated with less benefit than the target of <140 mm Hg in terms of all-cause mortality, cardiovascular mortality, stroke, and myocardial infarct. Moreover, results from SPRINT also demonstrated that lowering of SBP to 120 mm Hg reduces rates of major cardiovascular events and allcause mortality, suggesting that for SBP the lower goal is better to improve the health in older or high-risk patients. 7 A main finding of our study is the race-ethnic differences in the increased risk for SBP of 140 to 149 mm Hg compared with SBP <140 mm Hg, showing an increase by 2.6× in Hispanics and 1.9× in non-Hispanic blacks, but not in non-Hispanic whites (P=0.039 for heterogeneity between Hispanics and whites; P=0.148 for heterogeneity between blacks and whites; Table 2 ). Our results are in agreement with the concerns already reported from the Association of Black Cardiologists, 7 on the race-ethnicity gaps of the JCN8. The Association of Black Cardiologists supported the need for a more appropriate and drinking, physical activity, and history of myocardial infarct, atrial fibrillation, or coronary artery disease. Model 3: model 2 additionally adjusted for diastolic BP. P Het : P value for heterogeneity for effect comparison between Hispanic and white, between black and white, between men and women, and between age <80 and ≥80 years. CI indicates confidence interval; HR, hazards ratio; NH, non-Hispanic; and SBP, systolic blood pressure.
by guest on July 30, 2017 http://hyper.ahajournals.org/ Downloaded from stringent control of BP, especially in high-risk groups such as blacks where life expectancy is 5.4 years shorter than whites, and hypertension is the single largest contributor to this disparity. 25 In NOMAS, we previously demonstrated that overall the incidence of stroke was higher in Hispanic and Black populations than in whites, 18, 19 and similarly, the levels of BP were greater in these race-ethnic subgroups. 3 Moreover, less effective BP medications may be more frequently used in ethnic minority populations, and this can be one of the reasons of the higher levels of BP and higher incidence of stroke in Hispanics and blacks. 26 Interestingly, among those without any antihypertensive medications at baseline, our study showed a similar increased risk of stroke for those with SBP of 140 to 149 across race-ethnic subgroups (P>0.93 for heterogeneity; Table S1 ), suggesting that disparity in antihypertensive treatment may be an important contributor to the observed race-ethnic difference in the stroke risk. Given that the incidence of hypertension and stroke in Hispanics is high when compared with other raceethnicities, a major concern could be that the most recent JNC8 guidelines did not take into consideration the specific needs of these minority populations.
Another concern about the JNC8 recommendation is that women could be differentially affected by the recommendation to relax the SBP threshold for initiating treatment to 150 mm Hg. In the present study, women with SBP of 140 to 149 mm Hg had a 97% greater risk of stroke than women with SBP<140 mm Hg, and these risks tended to be more notable than among men. A similar concern about the JNC8 recommendation and risk for cardiovascular disease mortality among women with hypertension was already reported by the Working Group on Women's Cardiovascular Health. 7 The group raised this concern because most patients with hypertension aged ≥60 years are women. 20 Moreover, older women generally have poorly controlled BP and among those a high percentage are black women. 27, 28 When compared with JNC8, the European Society of Hypertension guidelines maintained the target BP of <140/90 mm Hg for the general population and recommended initiation of BP reduction therapy when SBP is >150 mm Hg only in patients aged >80 years. 29 Some studies and meta-analyses, conducted in old patients, suggested that achieving an SBP goal <140 mm Hg may increase the risk of side effects, such as orthostatic hypotension, 30 and increase risks of all-cause mortality. 31, 32 However, results from the Hypertension in the Very Elderly Trial (HYVET) 33 demonstrated that more aggressive treatment for hypertension in older people may have a benefit in terms of lower mortality for cardiovascular disease, especially for stroke. A meta-analysis performed on randomized controlled trials examining antihypertensive use in octogenarians concluded that hypertensive patients who are healthy and functionally independent should be treated according to current recommendations for people aged >65 years. 34 In the present study, we found that both subjects aged <80 years and those aged ≥80 years with SBP of 140 to 149 mm Hg had greater risk of stroke than those with SBP<140 mm Hg, suggesting that similar control of hypertension, even in elderly people, may result in better stroke prevention. For elderly patients, therapeutic BP goals are always less restrictive, depending on other comorbid conditions, frailty, and cognitive functions, but the reason to systematically increase the threshold for treatment of hypertension in all elderly patients is still debated.
Some studies demonstrated an inverse relationship, J-shaped, or U-shaped association between DBP and outcomes in elderly. 35, 36 Therefore, to further confirm our results, we excluded subjects with baseline DBP≥90 mm Hg to avoid bias related to DBP. After this exclusion, we confirmed the role of SBP in prediction of stroke and found similar results. When we reclassified our subgroups taking into account DBP levels, we also found similar trends of an increased stroke incidence for SBP 140 to 149 mm Hg among those with DBP<90 mm Hg (Table S1 ).
Strengths of our study include the community-based random-sampling method, the inclusion of a triethnic cohort with a sizeable number of Hispanics from the same community that allows comparisons and helps minimize socioeconomic confounding, the availability of comprehensive data on health behaviors, and the excellent retention of the cohort with follow-up for as long as 20 years. Nevertheless, several limitations also deserve mention. This is an observational study; therefore, biases present in observational data for generating hypothesis need to be considered. The sample size for whites and blacks, as well as for those aged >80 years, was relatively small, limiting the study's ability to prove differences in risk among subgroups. Also, SBP readings and patients' use of BP medications were based on a single baseline assessment and not time-dependent variables. Our cohort represents a lower socioeconomic, multiethnic, urban community and may not be representative of other populations.
Perspectives
We report a significantly greater incidence of stroke in subjects aged >60 years without DM and CKD who had a SBP of 140 to 149 mm Hg. This effect was more pronounced among minorities and women. Our data suggest that raising the systolic threshold for treatment of BP from 140 to 150 mm Hg as suggested by the JNC8 could lead to an increase in stroke risk and likely widen race, ethnic, and sex disparities for stroke. Our data support the adherence to the current American Heart Association recommendations that consistently recommend treatment for BP >140 to 90 mm Hg to improve cardiovascular health and reduce stroke.
• This is the first report to examine the effect of raising the systolic blood pressure threshold from 140 to 150 mm Hg for hypertension treatment on stroke risk in a prospective population-based cohort that represents a multiethnic community with a significant proportion of Hispanics.
What Is Relevant?
• Our findings indicate that systolic blood pressure between 140 and 149 mm Hg when compared with systolic blood pressure <140 mm Hg increases the risk of incident stroke in patients aged ≥60 years without diabetes mellitus or chronic kidney disease.
Summary
Raising the systolic blood pressure threshold from 140 to 150 mm Hg as a new target for hypertension treatment in older individuals without diabetes mellitus or chronic kidney disease could have a detrimental effect on stroke risk reduction, especially among minority US populations. Our data support adherence to the current American Heart Association recommendations that recommend treatment for BP >140 to 90 mm Hg to reduce stroke. 
Novelty and Significance
